Zhao Shui-Ping, Liu Ling, Cheng Yan-Chun, Li Yu-Ling
Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
Atherosclerosis. 2003 Jun;168(2):375-80. doi: 10.1016/s0021-9150(03)00142-4.
The effect of xuezhikang on postprandial triglyceride (TG) level was investigated in patients with coronary heart disease (CHD) after a high-fat meal (800 cal; 50 g fat). Fifty CHD patients were randomly divided into two groups to accept xuezhikang (xuezhikang group) 1200 mg/day (600 mg twice daily) or not (control group) on the base of routine therapy which included aspirin, metoprolol and fosinopril and nitrates during the whole 6 weeks following-up. Xuezhikang significantly reduced fasting serum total cholesterol (TC) (-20%), low-density lipoprotein cholesterol (LDL-C, -34%), TG (-32%) and apoB (-27%) levels, and raised fasting high-density lipoprotein cholesterol (HDL-C, 18%) and apoA-I (13%) levels (P<0.001). The postprandial serum TG levels at 2, 4 and 6 h decreased 32, 38 and 43%, respectively, in xuezhikang group (P<0.001). The TG area under the curve over the fasting TG level (TG-AUC) significantly decreased in CHD patients accepted xuezhikang with normal (less than 1.7 mmol/l) and elevated (1.74 to 2.92 mmol/l) fasting TG levels by 45 and 50%, respectively (P<0.001). Routine therapy had no significant effect on the fasting and postprandial lipid and apolipoprotein levels. The change of TG-AUC was significantly related to the changes of fasting TG, TC, LDL-C, and HDL-C levels after the treatment, which were related to the changes of fasting apoA-I and apoB levels significantly (P<0.001). Xuezhikang was shown to be beneficial in the treatment of reflecting postprandial triglyceridemia in CHD patients with normal and mildly elevated fasting TG levels.
研究血脂康对冠心病（CHD）患者高脂餐后餐后甘油三酯（TG）水平的影响。50例冠心病患者在接受包括阿司匹林、美托洛尔、福辛普利和硝酸盐类药物的常规治疗基础上，于整个6周随访期间，被随机分为两组，一组接受血脂康（血脂康组），每日1200毫克（600毫克，每日两次），另一组不接受（对照组）。血脂康显著降低空腹血清总胆固醇（TC）（-20%）、低密度脂蛋白胆固醇（LDL-C，-34%）、TG（-32%）和载脂蛋白B（-27%）水平，并升高空腹高密度脂蛋白胆固醇（HDL-C，18%）和载脂蛋白A-I（13%）水平（P<0.001）。血脂康组餐后2、4和6小时的血清TG水平分别下降32%、38%和43%（P<0.001）。空腹TG水平正常（低于1.7毫摩尔/升）和升高（1.74至2.92毫摩尔/升）的冠心病患者接受血脂康治疗后，空腹TG水平以上的TG曲线下面积（TG-AUC）分别显著下降45%和50%（P<0.001）。常规治疗对空腹和餐后血脂及载脂蛋白水平无显著影响。治疗后TG-AUC的变化与空腹TG、TC、LDL-C和HDL-C水平的变化显著相关，而这些变化又与空腹载脂蛋白A-I和载脂蛋白B水平的变化显著相关（P<0.001）。结果表明，血脂康对空腹TG水平正常和轻度升高的冠心病患者餐后甘油三酯血症的治疗有益。
